PharmaPhorum features Welldoc and Chief Marketing Officer, Marina Dorotheo, to learn more about the impact that the pandemic made on digital healthcare solutions and how access can be improved.
Following a breakthrough nod for Dexcom, CGMs may become a key part of hospital care.
#cgm
Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, today announced a first-of-its-kind Virtual Care Transformation Model. This strategic framework helps employers and health plans to assess and advance their healthcare programs by proactively integrating virtual care as a way of improving access, lowering costs and providing better health outcomes to individuals.
#virtual care
BD has set a record date of March 22, 2022 for the distribution of shares of embecta common stock.
Total revenue increased 171% from $7.6 million in 2020 to $20.5 million in 2021 on the strength of Dario's rapidly expanding growth resulting from the acquisitions closed in 2021 and the increasing sales in the B2B channel.
BIOCORP presents its agenda of investor meetings and professional conventions in the next few weeks. March 23 & 24, 2022 - French-speaking Diabetes Society (SFD) Congress in Nice (France). April 5, 2022 – Investor Access in Paris (France). April 27 to 30, 2022 – 15th ATTD (Advanced Technologies & Treatments for Diabetes) conference in Barcelona (Spain). May 16 & 17, 2022 – PDA Medical Devices and Connected Health Conference in Dublin (Ireland): presentation by Arnaud Guillet (Vice-President Business Development of BIOCORP). May 18 & 19, 2022 - Biocorp booth at Pharmapack Europe in Paris (France).
The market for diabetes care devices is estimated to reach a value of nearly $39,508.5 million in 2020, having grown at 7.2% since 2015 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% to nearly $54,309.8 million by 2025.
9am.health announced today that it now offers the Ascensia Diabetes Care Contour Next One and Contour Next products in its diabetes kit.
#connected device
#bgm
The social platform company is launching Dario's digital behavioral health solution to improve access to outcomes-based care for its employees; the health care company is deploying Dario's diabetes solution to provide employees with a solution proven to help people improve their health.
#dtx
Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that it will hold a call this Friday, March 25, to provide a deeper look at the results from the company’s pivotal clinical trial for BT-001, a prescription digital therapeutic for type 2 diabetes.